Study on Prevention and Treatment of Dry Eye in Patients Using Glaucoma Drops

NCT03515187 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2018-05-03

No results posted yet for this study

Summary

A multicenter randomized controlled trial on prevention and treatment of ocular surface injury and meibomian gland dysfunction in patients using anti-glaucoma eye drops.

Conditions

  • Dry Eye
  • MGD-Meibomian Gland Dysfunction

Interventions

DRUG

0.3% sodium hyaluronate ophthalmic solution

one to two drops in eye, four times per day

DRUG

0.1% sodium bromide solution

one to two drops in eye, twice per day

OTHER

Meibomian gland massage

Physiotherapy

OTHER

Placebo

Vehicle

Sponsors & Collaborators

  • Shenzhen Hospital of Southern Medical University

    lead OTHER

Principal Investigators

  • Yingli Li · Shenzhen Hospital of Southern Medicine University

  • Min Fu · Zhejiang Hospital

  • Lang Bai · Nanfang Hospital, Southern Medical University

  • Guanghua Zhou · The Fifth Affiliated Hospital of Southern Medical University

  • Lei Xi · Guangdong Provincial People's Hospital

  • Xiaolin Zhao · Shenzhen Hospital of Southern Medicine University

  • Wanli Liu · Shenzhen Hospital of Southern Medicine University

  • Yan Wang · Shenzhen Hospital of Southern Medicine University

  • Lina Chen · Shenzhen Hospital of Southern Medicine University

  • Sijing Zhang · Shenzhen Hospital of Southern Medicine University

  • Shingle An · Southern Medicine University

  • Liang Zhang · Guangdong Provincial People's Hospital

  • Ting Meng · Zhejiang Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-30
Primary Completion
2021-04-30
Completion
2021-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03515187 on ClinicalTrials.gov